{"id":533664,"date":"2021-09-02T07:04:27","date_gmt":"2021-09-02T11:04:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/"},"modified":"2021-09-02T07:04:27","modified_gmt":"2021-09-02T11:04:27","slug":"ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/","title":{"rendered":"AC Immune to Participate in Upcoming Virtual Investor Conferences in September"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LAUSANNE, Switzerland, Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences:<\/p>\n<p align=\"justify\">\n        <strong>Citi\u2019s 16<\/strong><br \/>\n        <sup><br \/>\n          <strong>th<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual BioPharma Virtual Conference<\/strong><br \/>\n        <br \/>One-on-one meetings \u2013 Wednesday, September 8, 2021<\/p>\n<p><strong>Morgan Stanley\u2019s 19<\/strong><sup><strong>th<\/strong><\/sup><strong> Annual Global Healthcare Conference<\/strong><br \/>One-on-one meetings \u2013 Friday, September 10, 2021 <\/p>\n<p><strong>H.C. Wainwright 23<\/strong><sup><strong>rd<\/strong><\/sup><strong> Annual Global Investment Conference<\/strong><br \/>Corporate presentation \u2013 On-demand starting on September 13, 2021<br \/>One-on-one meetings \u2013 Wednesday, September 15, 2021<\/p>\n<p align=\"justify\">During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company\u2019s corporate strategy and precision medicine approach, while highlighting its clinical-stage vaccine programs targeting phospho-Tau, Abeta, and alpha-synuclein in neurodegenerative diseases as well as the recent <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_3TMd9gKwimYLFKDokVUwBN2c3zZZbW5YNKZfcubIN0LQ-dpMOrjLzRXjZ5-Vn64Tsnv7fGFg2_PsvCOpH4a8HJ1OrIlvtgHrztTFaG_3iJIlXBE3z0_Tl6_hBzTsa8jqNtBLbREXtUcDpkJ9Az4utRXevZLfSc789hdfDHuCVSS5iIx1Y00F7QbWDRX0rokDwMX53PKDb6WMcc7FEqhy31kPnEB7x7rfUIA-Ql33CT8fo4IC6CQrLz0bteIzcFg\" rel=\"nofollow noopener\" target=\"_blank\">top-line data from Lauriet Phase 2 trial<\/a> evaluating semorinemab in mild-to-moderate AD.<\/p>\n<p align=\"justify\">A webcast of the corporate presentation will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=83gSfVfWN_tRfpUm7n2BGdsOcrOqJIDcvVZwg5IO6J0yDHEi0Dkgnk9v5hsGf1sogu94Km7Xt4j-cVC3ofVgJw==\" rel=\"nofollow noopener\" target=\"_blank\">Events Page<\/a> of AC Immune\u2019s website.<\/p>\n<p align=\"justify\">\n        <strong>About AC Immune SA <\/strong><br \/>\n        <br \/>AC Immune SA\u00a0is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen<sup>\u00ae<\/sup>\u00a0and Morphomer<sup>\u00ae<\/sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials.\u00a0AC Immune\u00a0has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including\u00a0Genentech, a member of the Roche Group, Eli Lilly and Company, and\u00a0Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$3 billion\u00a0in potential milestone payments.<\/p>\n<p align=\"justify\">SupraAntigen<sup>\u00ae<\/sup> is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU. Morphomer<sup>\u00ae<\/sup> is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.<\/p>\n<p align=\"justify\">\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:35%;width:35%;min-width:35%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Media Relations<\/strong><br \/>\n            <br \/>Saoyuth Nidh<br \/>AC Immune<br \/>Phone: +41 21 345 91 34<br \/>Email: <a href=\"mailto:saoyuth.nidh@acimmune.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>saoyuth.nidh@acimmune.com<\/u><\/a><\/td>\n<td style=\"max-width:65%;width:65%;min-width:65%;text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>Investor Relations<\/strong><br \/>\n            <br \/>Yves Kremer, Ph.D.<br \/>AC Immune<br \/>Phone: +41 21 345 91 90<br \/>Email: <a href=\"mailto:yves.kremer@acimmune.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>yves.kremer@acimmune.com<\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>U.S. Media<\/strong><br \/>\n            <br \/>Katie Gallagher<br \/>LaVoie Health Science<br \/>Phone: +1 617 792 3937<br \/>Email: <a href=\"mailto:kgallagher@lavoiehealthscience.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>kgallagher@lavoiehealthscience.com<\/u><\/a><\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>U.S. Investors<\/strong><br \/>\n            <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>Phone: +1 212 915 2577<br \/>Email:\u00a0<a href=\"mailto:cdavis@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Forward-looking statements<\/strong><br \/>\n        <br \/>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjZlMzNjZjItM2MzNC00MzU1LWEwMmEtMDQxZmE1ZTE1ZDliLTUwMDA2NDA0MQ==\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences: Citi\u2019s 16 th Annual BioPharma Virtual Conference One-on-one meetings \u2013 Wednesday, September 8, 2021 Morgan Stanley\u2019s 19th Annual Global Healthcare ConferenceOne-on-one meetings \u2013 Friday, September 10, 2021 H.C. Wainwright 23rd Annual Global Investment ConferenceCorporate presentation \u2013 On-demand starting on September 13, 2021One-on-one meetings \u2013 Wednesday, September 15, 2021 During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company\u2019s corporate strategy and precision medicine approach, while highlighting its clinical-stage vaccine programs targeting phospho-Tau, Abeta, and alpha-synuclein in neurodegenerative diseases as &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune to Participate in Upcoming Virtual Investor Conferences in September&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-533664","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune to Participate in Upcoming Virtual Investor Conferences in September - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune to Participate in Upcoming Virtual Investor Conferences in September - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences: Citi\u2019s 16 th Annual BioPharma Virtual Conference One-on-one meetings \u2013 Wednesday, September 8, 2021 Morgan Stanley\u2019s 19th Annual Global Healthcare ConferenceOne-on-one meetings \u2013 Friday, September 10, 2021 H.C. Wainwright 23rd Annual Global Investment ConferenceCorporate presentation \u2013 On-demand starting on September 13, 2021One-on-one meetings \u2013 Wednesday, September 15, 2021 During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company\u2019s corporate strategy and precision medicine approach, while highlighting its clinical-stage vaccine programs targeting phospho-Tau, Abeta, and alpha-synuclein in neurodegenerative diseases as &hellip; Continue reading &quot;AC Immune to Participate in Upcoming Virtual Investor Conferences in September&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T11:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune to Participate in Upcoming Virtual Investor Conferences in September\",\"datePublished\":\"2021-09-02T11:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/\"},\"wordCount\":606,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/\",\"name\":\"AC Immune to Participate in Upcoming Virtual Investor Conferences in September - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==\",\"datePublished\":\"2021-09-02T11:04:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune to Participate in Upcoming Virtual Investor Conferences in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune to Participate in Upcoming Virtual Investor Conferences in September - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune to Participate in Upcoming Virtual Investor Conferences in September - Market Newsdesk","og_description":"LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences: Citi\u2019s 16 th Annual BioPharma Virtual Conference One-on-one meetings \u2013 Wednesday, September 8, 2021 Morgan Stanley\u2019s 19th Annual Global Healthcare ConferenceOne-on-one meetings \u2013 Friday, September 10, 2021 H.C. Wainwright 23rd Annual Global Investment ConferenceCorporate presentation \u2013 On-demand starting on September 13, 2021One-on-one meetings \u2013 Wednesday, September 15, 2021 During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company\u2019s corporate strategy and precision medicine approach, while highlighting its clinical-stage vaccine programs targeting phospho-Tau, Abeta, and alpha-synuclein in neurodegenerative diseases as &hellip; Continue reading \"AC Immune to Participate in Upcoming Virtual Investor Conferences in September\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T11:04:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune to Participate in Upcoming Virtual Investor Conferences in September","datePublished":"2021-09-02T11:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/"},"wordCount":606,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/","name":"AC Immune to Participate in Upcoming Virtual Investor Conferences in September - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==","datePublished":"2021-09-02T11:04:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxODkxMiM0Mzg1MTYxIzUwMDA2NDA0MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune to Participate in Upcoming Virtual Investor Conferences in September"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=533664"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533664\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=533664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=533664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=533664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}